The Hsa-miR-27a rs895819 (A>G) polymorphism and cancer susceptibility.
The Hsa-miR-27a rs895819 (A>G) polymorphism and cancer susceptibility.
复制标题
DOI：
10.1016/j.gene.2013.02.042
复制
发表时间：
2013-05
期刊：
影响因子：
3.5
通讯作者：
Zexing Wang;Jing Lai;Yanru Wang;Weiwei Nie;X. Guan
中科院分区：
文献类型：
--
作者：
Zexing Wang;Jing Lai;Yanru Wang;Weiwei Nie;X. Guan
已发表的关于miR-27A前基因末端环rs895819(A>；G)多态与癌症风险之间的关联的数据尚不确定。因此，我们进行了一项荟萃分析，以评估该基因多态与癌症之间的关联。检索PubMed、Web of Science和Embase数据库中截至2012年11月24日发表的关于hsa-miR-27A rs895819多态与癌症风险的文章。在我们的荟萃分析中将搜索中获得的基因数据合并，并使用合并的优势比(OR)和95%的可信区间(CI)来评估这种关联。7项研究共3849例病例和4781例对照符合分析条件。总体而言，我们未发现hsa-miR-27A rs895819(A>；G)基因多态性与肿瘤易感性相关(纯合子模式：OR=0.88，95%CI：0.68-1.14；杂合子模式：OR=0.96，95%CI：0.79-1.17；显性模式：OR=0.94，95%CI：0.79-1.12；隐性模式：OR=0.88，95%CI：0.69-1.12)。在按种族划分的亚组分析中，我们发现rs895819 AG基因与白人个体患癌症的风险降低相关(显性模型：OR=0.85，95%CI：0.76-0.94；杂合子模型：OR=0.84，95%CI：0.75-0.94)。这一荟萃分析表明，在普通人群中，hsa-miR-27A rs895819多态与总体癌症风险无关。然而，rs895819 AG基因型可能会预防白人患癌症。需要对同种癌症患者进行更大、更好的研究，以进一步评估这种多态与癌症风险之间的相关性。
Published data on the association between the rs895819 (A>G) polymorphism in the terminal loop of pre-miR-27a and cancer risk is inconclusive. Therefore, we conducted a meta-analysis to estimate the association between this polymorphism and cancer. The PubMed, Web of science, and Embase databases were searched for articles on the hsa-miR-27a rs895819 polymorphism and cancer risk published up to November 24, 2012. The genotype data obtained in the searches were pooled in our meta-analysis, and pooled odds ratio (OR) with 95% confidence interval (CI) was used to assess the association. Seven studies with a total of 3849 cases and 4781 controls were eligible for analysis. Overall, we found no significant associations between the hsa-miR-27a rs895819 (A>G) polymorphism and cancer susceptibility (homozygote model: OR=0.88, 95% CI: 0.68–1.14; heterozygote model: OR=0.96, 95% CI: 0.79–1.17; dominant model: OR=0.94, 95% CI: 0.79–1.12; recessive model: OR=0.88, 95% CI: 0.69–1.12). In the subgroup analysis by ethnicity, we found that the rs895819 AG genotype was associated with a decreased risk of cancer in white individuals (dominant model: OR=0.85, 95% CI: 0.76–0.94; heterozygote model: OR=0.84, 95% CI: 0.75–0.94). This meta-analysis indicated that the hsa-miR-27a rs895819 polymorphism did not correlate with overall cancer risk in the general population. However, the rs895819 AG genotype may protect against the development of cancer in white individuals. Larger, better studies of homogeneous cancer patients are needed to further assess the correlation between this polymorphism and cancer risk.